Thyrocare Technologies Limited
NSE:THYROCARE.NS
831.05 (INR) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 5,718.8 | 5,266.7 | 5,888.6 | 4,946.2 | 4,332 | 4,029.1 | 3,563.15 | 3,068.06 | 2,409.65 | 1,829.58 | 1,502.3 | 1,342.61 |
| Cost of Revenue
| 3,215.7 | 1,632.3 | 1,696.9 | 1,639 | 1,170.9 | 1,105.3 | 949.72 | 893.28 | 735.67 | 583.12 | 558.99 | 461.82 |
| Gross Profit
| 2,503.1 | 3,634.4 | 4,191.7 | 3,307.2 | 3,161.1 | 2,923.8 | 2,613.43 | 2,174.78 | 1,673.98 | 1,246.46 | 943.31 | 880.79 |
| Gross Profit Ratio
| 0.438 | 0.69 | 0.712 | 0.669 | 0.73 | 0.726 | 0.733 | 0.709 | 0.695 | 0.681 | 0.628 | 0.656 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.5 | 0 | 0 | 0 |
| General & Administrative Expenses
| 1,431.5 | 233.5 | 173.8 | 133.5 | 153.5 | 166.8 | 115.35 | 83.68 | 66.11 | 45.02 | 0.74 | 0.56 |
| Selling & Marketing Expenses
| 167.4 | 191.9 | 213 | 238.9 | 235.1 | 239.8 | 198.7 | 141.89 | 40.03 | 34.24 | 55.8 | 47.05 |
| SG&A
| 1,598.9 | 425.4 | 386.8 | 372.4 | 388.6 | 406.6 | 314.05 | 225.57 | 106.14 | 79.26 | 56.54 | 47.61 |
| Other Expenses
| 93.7 | 84.2 | 18 | 21.2 | 22.1 | 41 | 70.03 | 18.52 | 788.77 | 562.8 | 0 | 0 |
| Operating Expenses
| 1,598.9 | 2,821 | 2,181.5 | 1,895.9 | 1,755 | 1,642.9 | 1,349.73 | 1,166.51 | 894.91 | 642.06 | 288.5 | 144.33 |
| Operating Income
| 904.2 | 813.9 | 2,010.2 | 1,411.2 | 1,416.6 | 1,291.1 | 1,263.7 | 1,008.27 | 779.07 | 604.4 | 625.7 | 601.49 |
| Operating Income Ratio
| 0.158 | 0.155 | 0.341 | 0.285 | 0.327 | 0.32 | 0.355 | 0.329 | 0.323 | 0.33 | 0.416 | 0.448 |
| Total Other Income Expenses Net
| 51.7 | 72 | 267 | 113.5 | -12.5 | 89.5 | 186.24 | 85.88 | 38.96 | 60.99 | 63.25 | 177.25 |
| Income Before Tax
| 955.9 | 885.9 | 2,277.2 | 1,524.7 | 1,404.2 | 1,380.6 | 1,449.94 | 1,094.15 | 818.03 | 665.39 | 688.95 | 778.74 |
| Income Before Tax Ratio
| 0.167 | 0.168 | 0.387 | 0.308 | 0.324 | 0.343 | 0.407 | 0.357 | 0.339 | 0.364 | 0.459 | 0.58 |
| Income Tax Expense
| 264.9 | 242.3 | 515.8 | 393.2 | 520.1 | 529.2 | 517.19 | 384.5 | 300.03 | 230.68 | 227.39 | 210.55 |
| Net Income
| 707.6 | 644.9 | 1,761.4 | 1,131.5 | 884 | 851.4 | 932.75 | 709.65 | 518 | 446.5 | 461.56 | 568.19 |
| Net Income Ratio
| 0.124 | 0.122 | 0.299 | 0.229 | 0.204 | 0.211 | 0.262 | 0.231 | 0.215 | 0.244 | 0.307 | 0.423 |
| EPS
| 13.42 | 12.16 | 33.3 | 21.41 | 16.74 | 15.95 | 17.36 | 8 | 10.06 | 9.14 | 10.57 | 13.01 |
| EPS Diluted
| 13.4 | 12.14 | 33.24 | 21.37 | 16.7 | 15.91 | 17.32 | 7.98 | 10.06 | 9.14 | 10.57 | 13.01 |
| EBITDA
| 1,374.3 | 1,296.5 | 2,372.2 | 1,741 | 1,759.4 | 1,595.9 | 1,562.96 | 1,167.31 | 961 | 733.22 | 689.32 | 634.64 |
| EBITDA Ratio
| 0.24 | 0.246 | 0.403 | 0.352 | 0.406 | 0.396 | 0.439 | 0.38 | 0.399 | 0.401 | 0.459 | 0.473 |